Redback Spider AntiVenom Evaluation (RAVE) Study

Randomised controlled trial of antivenom for the treatment of pain in redback spider bite; intravenous versus intramuscular antivenom.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000146695

Acronym

RAVE

Enrollment

130

Registered

2005-08-15

Start date

2003-01-19

Completion date

2007-03-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study has been published A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study. Isbister GK, Brown SG, Miller M, Tankel A, Macdonald E, Stokes B, Ellis R, Nagree Y, Wilkes GJ, James R, Short A, Holdgate A. QJM. 2008 Jul;101(7):557-65.

Interventions

The study compares 2 methods of administration of the same antivenom. The "active" group is intravenous antivenom (500U redback spider antivenom [CSL Ltd] diluted in 200 mL normal saline and given over 20 minutes; patient also receives a dummy intramuscual injection of 0.5mL normal saline).

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

8 Years to No maximum

Healthy volunteers

Inclusion criteria

(1) definite redback spider-bite and the spider is identified by the patient or clinician at the time of the bite; OR (2) clinical syndrome that is consistent with typical redback envenoming; AND the treating clinician would normally treat the patient with antivenom, namely: - moderate envenoming = severe local pain without systemic envenoming- severe envenoming = severe local pain and systemic features.

Exclusion criteria

1. Patients who have received antivenom for this envenoming prior to enrolment2. Children aged <8 years 3. Bite occurring >24 hours ago

Outcome results